Luciano Potena

ORCID: 0000-0001-7388-5012
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Transplantation: Methods and Outcomes
  • Renal Transplantation Outcomes and Treatments
  • Mechanical Circulatory Support Devices
  • Cardiac Structural Anomalies and Repair
  • Viral Infections and Immunology Research
  • Organ Transplantation Techniques and Outcomes
  • Cytomegalovirus and herpesvirus research
  • Cardiac Arrest and Resuscitation
  • Cardiac pacing and defibrillation studies
  • Heart Failure Treatment and Management
  • Cardiac Valve Diseases and Treatments
  • Cardiovascular Function and Risk Factors
  • Herpesvirus Infections and Treatments
  • Polyomavirus and related diseases
  • Cardiomyopathy and Myosin Studies
  • Pulmonary Hypertension Research and Treatments
  • Adenosine and Purinergic Signaling
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Organ Donation and Transplantation
  • Neurological Complications and Syndromes
  • SARS-CoV-2 and COVID-19 Research
  • Folate and B Vitamins Research
  • COVID-19 Clinical Research Studies
  • Organ and Tissue Transplantation Research
  • Cardiac electrophysiology and arrhythmias

University of Bologna
2016-2025

Policlinico S.Orsola-Malpighi
2016-2025

Azienda USL di Bologna
2021-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024

European Society for Blood and Marrow Transplantation
2024

International Society for Heart and Lung Transplantation
2016-2023

ERN GUARD-Heart
2023

Presidio Ospedaliero
2023

Accademia Italiana Medicina Osteopatica
2023

University of Brescia
2023

In an open-label, 24-month trial, 721 <i>de novo</i> heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 with reduced-dose cyclosporine, mycophenolate mofetil (MMF) 3 g/day standard-dose cyclosporine (plus corticosteroids ± induction). Primary efficacy endpoint was the 12-month composite incidence of biopsy-proven acute rejection, rejection associated hemodynamic compromise, graft loss/retransplant, death loss follow-up. Everolimus noninferior MMF for this at month 12...

10.1111/ajt.12181 article EN cc-by-nc-nd American Journal of Transplantation 2013-02-23

The aim of this study was to characterize left atrial (LA) pathology in explanted hearts with transthyretin amyloid cardiomyopathy (ATTR-CM); LA mechanics using echocardiographic speckle-tracking a large cohort patients ATTR-CM; and the association mortality.The clinical significance involvement ATTR-CM is great interest.Congo red staining immunohistochemistry performed assess presence, type, extent associated changes 5 atria. Echo speckle tracking used reservoir, conduit, contractile...

10.1016/j.jcmg.2021.06.022 article EN cc-by-nc-nd JACC. Cardiovascular imaging 2021-08-19
Coming Soon ...